Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pugh

Showing results (541-550 of 602) with videos related to

Pageof 61
Sort By:
Nature Genetics|October 11, 2016
The genomic landscape of schwannomaSameer Agnihotri, Shahrzad Jalali, Mark R Wilson, et al.
Journal of the National Cancer Institute|September 9, 2023
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survivalJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Nature Communications|January 25, 2020
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancerStanley Zhou, James R Hawley, Fraser Soares, et al.
Cancer Discovery|October 1, 2013
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsEsra A Akbay, Shohei Koyama, Julian Carretero, et al.
Cell Genomics|February 13, 2023
CanDIG: Federated network across Canada for multi-omic and health data discovery and analysisL Jonathan Dursi, Zoltan Bozoky, Richard de Borja, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity studyMarc Oliva, Douglas Chepeha, Daniel V Araujo, et al.
Genome Medicine|December 4, 2021
A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing geneCaitlin T Fierheller, Laure Guitton-Sert, Wejdan M Alenezi, et al.
Nature Communications|January 3, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trialApril A N Rose, Jennifer Maxwell, Emmanuelle Rousselle, et al.
Immunity|February 9, 2022
Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunityKebria Hezaveh, Rahul S Shinde, Andreas Klötgen, et al.
Genome Biology|August 11, 2010
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsSteven Jm Jones, Janessa Laskin, Yvonne Y Li, et al.
Pageof 61

Showing results (541-550 of 602) with videos related to

Sort By:
Pageof 61
Nature Genetics|October 11, 2016
The genomic landscape of schwannomaSameer Agnihotri, Shahrzad Jalali, Mark R Wilson, et al.
Journal of the National Cancer Institute|September 9, 2023
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survivalJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Nature Communications|January 25, 2020
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancerStanley Zhou, James R Hawley, Fraser Soares, et al.
Cancer Discovery|October 1, 2013
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsEsra A Akbay, Shohei Koyama, Julian Carretero, et al.
Cell Genomics|February 13, 2023
CanDIG: Federated network across Canada for multi-omic and health data discovery and analysisL Jonathan Dursi, Zoltan Bozoky, Richard de Borja, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity studyMarc Oliva, Douglas Chepeha, Daniel V Araujo, et al.
Genome Medicine|December 4, 2021
A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing geneCaitlin T Fierheller, Laure Guitton-Sert, Wejdan M Alenezi, et al.
Nature Communications|January 3, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trialApril A N Rose, Jennifer Maxwell, Emmanuelle Rousselle, et al.
Immunity|February 9, 2022
Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunityKebria Hezaveh, Rahul S Shinde, Andreas Klötgen, et al.
Genome Biology|August 11, 2010
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsSteven Jm Jones, Janessa Laskin, Yvonne Y Li, et al.
Pageof 61